Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 6;30(4):824–835. doi: 10.1158/1078-0432.CCR-23-1689

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2023 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 4. Subgroup analysis of OS by tTMB for durvalumab plus tremelimumab plus EP versus EP (A) and durvalumab plus EP versus EP (B). In each panel, the shaded band shows the CI for the ITT population; circle sizes are proportional to the number of events. BEP, biomarker evaluable population; CI, confidence interval; D, durvalumab; EP, platinum-etoposide; HR, hazard ratio; ITT, intention-to-treat; OS, overall survival; mut/Mb, mutations per megabase; T, tremelimumab; tTMB, tissue tumor mutational burden. — Subgroup analysis of OS by tTMB for durvalumab plus EP versus EP (A) and durvalumab plus tremelimumab plus EP versus EP (B). In each panel, the shaded band shows the CI for the ITT population; circle sizes are proportional to the number of events. BEP, biomarker evaluable population; CI, confidence interval; D, durvalumab; EP, platinum-etoposide; HR, hazard ratio; ITT, intention-to-treat; OS, overall survival; mut/Mb, mutations per megabase; T, tremelimumab; tTMB, tissue tumor mutational burden.